The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
BEACON-HCC: Best evidence and North American consensus on treatment allocation for hepatocellular carcinoma
Open accessAbstract
Background : Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality. Optimal treatment decisions are challenging, and existing treatment allocation frameworks may not fully reflect the evolving therapeutic landscape or contemporary clinical practices in North America. Methods : Using a modified Delphi process, a multidisciplinary panel of 20 North American experts in hepatology, medical oncology, surgery, radiology, and radiation oncology developed a consensus-based treatment framework for HCC, termed the BEACON-HCC system. The framework was informed by current evidence and expert opinion through iterative discussion and voting. In a pilot study using 29 real-world patient cases, we assessed concordance between external expert recommendations and BEACON-HCC recommendations and Barcelona Clinic Liver Cancer (BCLC) 2025 treatment recommendations. Results : The BEACON-HCC treatment allocation framework diverges from prior frameworks by incorporating nuanced clinical features such as degree of intrahepatic tumor burden and vascular invasion, and adverse tumor prognostic markers, to align treatment allocation with tumor biology and therapeutic potential. Key innovations include the incorporation of emerging modalities such as external beam radiation therapy (EBRT), transarterial radioembolization (TARE), and systemic-locoregional combination therapies. In the pilot exercise, expert treatment decisions showed 96.6% concordance with BEACON-HCC recommendations and 72.4% concordance with BCLC recommendations. Conclusions : BEACON-HCC is a consensus-based framework for treatment allocation that incorporates the expanding range of therapeutic options available to patients in the North American HCC population. Expert treatment decisions showed a high concordance with the BEACON-HCC system; further validation using empiric clinical data is planned through the HCC-Live Consortium.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186
Llovet, J. M., & Bruix, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50047 · Cited by 3,029
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052
Self-citationCheng, A.-L., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Lim, H. Y., Kudo, M., Breder, V., Merle, P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.030 · Cited by 1,743
Self-citationBruix, J., Takayama, T., Mazzaferro, V., Chau, G.-Y., Yang, J., Kudo, M., Cai, J., Poon, R. T., Han, K.-H., Tak, W. Y., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00198-9 · Cited by 1,120
Bujold, A., Massey, C. A., Kim, J. J., Brierley, J., Cho, C., Wong, R. K. S., Dinniwell, R. E., Kassam, Z., Ringash, J., Cummings, B., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.1659 · Cited by 820
Self-citationRadiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors
Shiina, S., Tateishi, R., Arano, T., Uchino, K., Enooku, K., Nakagawa, H., Asaoka, Y., Sato, T., Masuzaki, R., Kondo, Y., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.425 · Cited by 724
Beiderbeck, D., Frevel, N., von der Gracht, H. A., Schmidt, S. L., & Schweitzer, V. M. (2021) · MethodsX · doi:10.1016/j.mex.2021.101401 · Cited by 642
Garin, E., Tselikas, L., Guiu, B., Chalaye, J., Edeline, J., de Baere, T., Assenat, E., Tacher, V., Robert, C., Terroir-Cassou-Mounat, M., et al. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30290-9 · Cited by 630
Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study
Salem, R., Johnson, G. E., Kim, E., Riaz, A., Bishay, V., Boucher, E., Fowers, K., Lewandowski, R., & Padia, S. A. (2021) · Hepatology · doi:10.1002/hep.31819 · Cited by 555
Self-citation
Research works printed but not linked: 3
- Tabrizian, 2022, Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma, JAMA Surg, 157, 779
- Finn, 2024, Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma with main trunk and/or contralateral portal vein invasion in IMbrave150, Liver Cancer, 13, 655
- Abou-Alfa, 2021, Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma, N Engl J Med Evidence, 1, 1
Cited by
Yarchoan, M. M., Llovet, J. M., Kelley, R. K., Finn, R., Parikh, N. D., Tabrizian, P., Burgoyne, A., Agopian, V. G., Sanford, N. N., Cao, H. S. T., et al. (2026) · Gut · doi:10.1136/gutjnl-2026-339505 · Cited by 1
Self-citationBEACON-HCC through the lens of a large U.S. multidisciplinary program
Johnson, M. S., Holden, J., & Turk, A. A. (2026) · Hepatology · doi:10.1097/hep.0000000000001850
Light across the Pacific Ocean: An Asian perspective on BEACON-HCC
Yau, T. W. C., Yuen, M.-F., & Cheung, T.-T. (2026) · Hepatology · doi:10.1097/hep.0000000000001857
Precision surgical oncology for hepatocellular carcinoma
Okabayashi, T., Tabuchi, M., Tokumaru, T., Uemura, S., & Tamura, S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1957598
The Landmark Series: Perioperative Management of Hepatocellular Carcinoma
Nahi, S. L., & Yopp, A. C. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-20690-5
Self-citation
Metadata
- Authors
- Singal, A. G., Agopian, V. G., Dawson, L. A., El-Khoueiry, A., Finn, R. S., Halazun, K., Heimbach, J. K., Kelley, R. K., Kim, E., Kulik, L., Mehta, N., Mendiratta-Lala, M., Meyer, J., Parikh, N. D., Pillai, A., Salem, R., Sapisochin, G., Tabrizian, P., Yopp, A., Yarchoan, M., & on behalf of HCC-Live Steering Committee
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- University of California, Los Angeles (US)
- University of Toronto (CA)
- University of Southern California (US)
- NYU Langone Health (US)
- Mayo Clinic (US)
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA
- Icahn School of Medicine at Mount Sinai (US)
- Northwestern University (US)
- University of California, San Francisco (US)
- Department of Radiology, University of Michigan, Ann Arbor, Michigan, USA
- Johns Hopkins University (US)
- University of Michigan (US)
- University of Chicago (US)
- Department of Abdominal, General Surgery and Liver Transplantation, Hospital Universitario Vall d´Hebron, Barcelona, Spain
- Mount Sinai Hospital (US)
- ORCID
- Venue
- Hepatology
- Published
- 2026-08-07
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W7201851864
- Semantic Scholar
- 15a0e77795fcb88f0fd45d962b8c2979ab6a1cc3
- Cited by
- 7
- References
- 66
- Citations by year
- 2026: 7
- FWCI
- 28.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Hepatology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Social Sciences › Sociology and Political Science › Delphi Technique in Research
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Keywords
- hepatocellular carcinoma, treatment allocation, external beam radiotherapy, radioembolization, vascular invasion, prognostic factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BEACON-HCC: Best evidence and North American consensus on treatment allocation for hepatocellular carcinoma. https://app.cochat.ai/papers/10.1097/hep.0000000000001834
- The paper
- Singal, A. G., Agopian, V. G., Dawson, L. A., El-Khoueiry, A., Finn, R. S., Halazun, K., Heimbach, J. K., Kelley, R. K., Kim, E., Kulik, L., Mehta, N., Mendiratta-Lala, M., Meyer, J., Parikh, N. D., Pillai, A., Salem, R., Sapisochin, G., Tabrizian, P., Yopp, A., . . . on behalf of HCC-Live Steering Committee. (2026). BEACON-HCC: Best evidence and North American consensus on treatment allocation for hepatocellular carcinoma. Hepatology. https://doi.org/10.1097/hep.0000000000001834
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.